Search company, investor...

Twinstrand Therapeutics

twinstrand.com

Founded Year

2004

Stage

Acquired | Acquired

Total Raised

$6.5M

Valuation

$0000 

About Twinstrand Therapeutics

Twinstrand has established a technology that uses modified versions of ricin, a plant-derived cell toxin, as therapeutic prodrugs. Its lead drug, a product known as TST10088, is currently undergoing a Phase I clinical trial. The prodrugs leave healthy cells unaffected while specific chemical activity within targeted diseased cells activates the cell-killing activities of the drug. As a spin-off from its original focus, Twinstrand has also begun developing anti-ricin, antibody-based therapeutics;

Headquarters Location

267 West Esplanade Suite 309

North Vancouver, British Columbia, V7M 1A5,

Canada

Missing: Twinstrand Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Twinstrand Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Twinstrand Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Twinstrand Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Twinstrand Therapeutics Frequently Asked Questions (FAQ)

  • When was Twinstrand Therapeutics founded?

    Twinstrand Therapeutics was founded in 2004.

  • Where is Twinstrand Therapeutics's headquarters?

    Twinstrand Therapeutics's headquarters is located at 267 West Esplanade, North Vancouver.

  • What is Twinstrand Therapeutics's latest funding round?

    Twinstrand Therapeutics's latest funding round is Acquired.

  • How much did Twinstrand Therapeutics raise?

    Twinstrand Therapeutics raised a total of $6.5M.

  • Who are the investors of Twinstrand Therapeutics?

    Investors of Twinstrand Therapeutics include Cangene and GrowthWorks.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.